secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001323885-21-000048
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q3 revenue $70.5M, +28.7% YoY; adj EPS -$0.23; FY guide reaffirmed
---------------------------------------------------------------------------

- Revenue $70.5M, up 28.7% YoY (28.6% constant currency); U.S. $57.5M (+28.7%), intl $12.9M (+28.5%).
- GAAP income from operations $98.7M vs loss $4.0M, driven by $189.9M fair value credit and $82.3M impairment charge.
- Adjusted EBITDA $0.7M positive vs $4.2M positive; adjusted loss per share $0.23 vs $0.11 loss.
- Maintains FY2021 revenue guidance $270-275M (~31-33% growth); adj EBITDA loss ~$10M; adj EPS loss ~$1.20.
- CEO cites growth in Cryo Nerve Block and Hybrid AF accounts; delta variant impacts felt across the country.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388521000048/0001323885-21-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388521000048/atrc-20211103.htm
  HTML page:      https://secwatch.observer/filing/0001323885-21-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer